摘要
表皮细胞生长因子受体酪氨酸激酶抑制剂(EGFR-TKIs)是肺癌治疗中具有里程碑意义的一次转折,使患者的生存时间得到了实质性的延长。口腔黏膜炎(oral mucositis,OM)是EGFR-TKIs治疗肿瘤过程中产生的常见并发症之一。临床表现为口腔黏膜红斑、水肿、糜烂、溃疡,表面可覆盖假膜、渗血以及组织坏死,导致疼痛,严重影响进食,使患者身体营养状况和耐受治疗能力下降,导致患者EGFR-TKIs治疗中止。EGFR--TKIs相关口腔黏膜炎的防治对于保证EGFR-TKIs治疗的顺利进行,提高患者生活质量十分重要。本文在对EGFR-TKIs相关口腔黏膜炎的临床表现、发病机制研究进展进行综述的基础上,对EGFR-TKIs相关口腔黏膜炎防治管理进行了阐述,提出EGFR-TKIs相关口腔黏膜炎早期预防、早期发现、早期处置和全程监测的思路,旨在加强临床医生对EGFR-TKIs相关口腔黏膜炎的认知和防治,为EGFR-TKIs等癌症靶向药物的临床应用保驾护航。
Epidermal growth factor receptor tyrosine kinase inhibitors(EGFR-TKIs)are considered to be a landmark turning point in the treatment of lung cancer,which has substantially extended the survival time of patients.Oral mucositis(OM)is one of the common complications in the treatment of tumors with EGFR-TKIs,which is manifested as oral mucosal erythema,edema,erosion,and ulcers.The oral mucosa can be covered with pseudomembrane,oozed blood,and caused necrosis and pain,which seriously hindered food intake,reduced patients'nutrition and tolerance to treatment,and led to failure in patient's EGFR-TKIs treatment.The prevention and treatment of EGFR-TKIs-related oral mucositis is crucial to ensure the smooth progress of EGFR-TKIs treatment and improve the quality of life of patients.Based on the review of clinical manifestations and pathogenesis of EGFR-TKIs-related oral mucositis,this paper illustrates the prevention and management of EGFR-TKIs-related oral mucositis,and proposes the early discovery,early prevention,and full-process monitor of EGFR-TKIs-related oral mucositis in an effort to strengthen clinicians'awareness,thus facilitating the clinical application of EGFR-TKIs and other cancer-targeted drugs.
作者
王文梅
段宁
WANG Wenmei;DUAN Ning(Stomatological Hospital of Nanjing University, Nanjing Stomatological Hospital, Nanjing 210008, China.)
出处
《口腔医学研究》
CAS
CSCD
北大核心
2021年第10期869-874,共6页
Journal of Oral Science Research
